Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Cell Reports|February 10, 2021
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humansHenry J Sutton, Racheal Aye, Azza H Idris, et al.The New England Journal of Medicine|November 1, 2022
Safety and Efficacy of a Monoclonal Antibody against Malaria in MaliKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.Science Translational Medicine|June 24, 2021
Functional human IgA targets a conserved site on malaria sporozoitesJoshua Tan, Hyeseon Cho, Tossapol Pholcharee, et al.Immunity|November 17, 2021
Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodiesSven Kratochvil, Chen-Hsiang Shen, Ying-Cing Lin, et al.Immunity|September 18, 2020
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the LiverLawrence T Wang, Lais S Pereira, Yevel Flores-Garcia, et al.The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.Nature Medicine|December 16, 2018
Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasiteNeville K Kisalu, Azza H Idris, Connor Weidle, et al.The New England Journal of Medicine|April 26, 2024
Subcutaneous Administration of a Monoclonal Antibody to Prevent MalariaKassoum Kayentao, Aissata Ongoiba, Anne C Preston, et al.Nature Medicine|March 20, 2018
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasiteNeville K Kisalu, Azza H Idris, Connor Weidle, et al.The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.Pageof 4